GO:0005896 interleukin-6 receptor complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005896 (interleukin-6 receptor complex) is a hexameric cellular component composed of two molecules each of IL-6, IL-6R alpha (IL6R), and gp130 (IL6ST).
• Assembly of this complex triggers gp130 dimerization and activation of JAK/STAT3, MAPK, and PI3K signaling, which drives both pro- and anti-inflammatory gene programs.
• A soluble form of IL-6R (sIL-6R) can bind IL-6 and activate gp130 on cells that lack membrane-bound IL-6R, a process called IL-6 trans-signaling.
• Dysregulated IL-6 receptor complex signaling is central to cytokine storm syndromes, chronic inflammation, and multiple cancers.
• The complex is a validated drug target: tocilizumab blocks IL-6R, while sgp130Fc selectively inhibits trans-signaling.
• CRISPR knockout, knock-in, and overexpression models of IL6, IL6R, and IL6ST are essential for dissecting ligand-dependent versus trans-signaling outputs.
Description
The interleukin-6 receptor complex (GO:0005896) is the hexameric signaling assembly through which the cytokine interleukin-6 (IL-6) transmits extracellular information into the cytoplasm. According to QuickGO, this cellular component consists of two molecules each of IL-6, the interleukin-6 receptor alpha chain (IL6R), and the signal-transducing subunit gp130 (IL6ST). Because IL-6 controls fever, acute-phase protein production, B-cell and T-cell differentiation, and hematopoiesis, the receptor complex sits at the crossroads of innate and adaptive immunity. Researchers study GO:0005896 to understand how a single cytokine can produce context-dependent pro-inflammatory or regenerative outputs, and to design biologics that selectively block pathogenic signaling while preserving homeostatic functions. The complex is also a paradigm for cytokine receptor assembly: ligand binding to IL6R creates a composite surface that recruits gp130, which then dimerizes and activates associated Janus kinases (JAKs). This mechanism explains why IL-6 signaling can be targeted at multiple levels, from the ligand itself to the receptor alpha chain, gp130, or the soluble decoy sgp130. In this article we integrate the QuickGO definition with verified PubMed literature to describe the structure, assembly, regulation, disease relevance, and CRISPR-based research methods for GO:0005896.
interleukin-6 receptor complex At A Glance
| GO ID | GO:0005896 |
|---|---|
| GO term | interleukin-6 receptor complex |
| Ontology | cellular_component |
| Synonym | IL-6 receptor complex |
| Definition | A hexameric protein complex consisting of two molecules each of interleukin-6, interleukin-6 receptor alpha chain, and gp-130. |
| Major function | Mediates IL-6 signal transduction via gp130 dimerization and JAK/STAT activation. |
| Stoichiometry | 2 x IL-6 : 2 x IL6R : 2 x gp130 (hexamer). |
| Key subunits | IL6 (ligand), IL6R (alpha chain), IL6ST/gp130 (signal transducer). |
| Soluble variant | sIL-6R can replace membrane IL6R to drive trans-signaling. |
What Is GO:0005896?
GO:0005896 describes a hexameric protein complex made of two IL-6 molecules, two IL-6 receptor alpha chains, and two gp130 molecules. It is the membrane-associated receptor assembly that forms when IL-6 binds IL6R and recruits gp130, enabling signal transduction across the plasma membrane.
Why Is interleukin-6 receptor complex Important in Cell Biology?
GO:0005896 is important because it converts a pleiotropic cytokine signal into defined transcriptional programs that control inflammation, immunity, metabolism, and tissue regeneration. The same complex can drive protective acute-phase responses in the liver and, when chronically activated, promote autoimmune pathology, cytokine storm, and tumor progression. Understanding its assembly and regulation is therefore essential for therapeutic targeting of IL-6 signaling in human disease.
• Central to acute-phase response and host defense in the liver.
• Drives B-cell and T-cell differentiation and antibody production.
• Mediates fever and systemic inflammatory responses.
• Contributes to cytokine storm syndromes and hyperinflammation.
• Promotes tumor growth and survival in multiple cancers.
• Supports tissue regeneration and metabolic homeostasis.
• Serves as a validated target for anti-IL-6R therapeutics such as tocilizumab.
• Trans-signaling via sIL-6R expands the range of responsive cells.
• Provides a structural paradigm for cytokine receptor assembly.
• Enables CRISPR-based dissection of ligand-dependent versus trans-signaling outputs.
What Happens During interleukin-6 receptor complex?
Ligand binding and receptor assembly
In simple terms: IL-6 first grabs the IL-6 receptor alpha chain, and together they create a docking site for gp130.
IL-6 binds with high affinity to the membrane-bound IL-6 receptor alpha chain (IL6R), forming a binary IL-6/IL6R complex. This binary complex then recruits two molecules of the signal-transducing subunit gp130 (IL6ST), generating the hexameric interleukin-6 receptor complex defined by GO:0005896. The assembly is sequential and cooperative, and the resulting hexamer is the minimal unit capable of initiating downstream signaling.
gp130 dimerization and JAK activation
In simple terms: Once gp130 molecules are brought together, they switch on enzymes called JAKs that phosphorylate the receptor tail.
Dimerization of gp130 in the hexameric complex brings associated Janus kinases (JAK1, JAK2, TYK2) into close proximity, enabling trans-phosphorylation and activation. Activated JAKs phosphorylate tyrosine residues in the cytoplasmic domain of gp130, creating docking sites for STAT3 and other signaling proteins. This step is the committed event that converts extracellular IL-6 binding into intracellular signal transduction.
STAT3 activation and transcriptional output
In simple terms: STAT3 proteins dock on gp130, get phosphorylated, pair up, and move to the nucleus to turn genes on or off.
Recruited STAT3 is phosphorylated by JAKs, dimerizes, and translocates to the nucleus, where it regulates target genes involved in inflammation, survival, and proliferation. The same complex also activates MAPK and PI3K pathways, contributing to context-dependent outputs. The balance between STAT3 and other pathways determines whether IL-6 acts pro- or anti-inflammatory.
Trans-signaling via soluble IL-6R
In simple terms: A soluble version of the receptor can carry IL-6 to cells that normally lack the membrane receptor, widening the response.
Soluble IL-6R (sIL-6R) generated by shedding or alternative splicing binds IL-6 and activates gp130 on cells that do not express membrane IL6R, a process termed IL-6 trans-signaling. Trans-signaling is strongly associated with the pro-inflammatory actions of IL-6, whereas classic signaling via membrane IL6R mediates regenerative and anti-inflammatory effects. The soluble decoy sgp130 selectively inhibits trans-signaling without blocking classic signaling.
Negative regulation and desensitization
In simple terms: Cells use brakes such as SOCS proteins and phosphatases to shut down the signal after it has done its job.
SOCS1 and SOCS3 are induced by STAT3 and feedback to inhibit JAK activity, limiting the duration of interleukin-6 receptor complex signaling. Phosphatases such as SHP2 and receptor internalization further attenuate the response. Dysregulation of these brakes contributes to persistent inflammation and disease.
Key Genes Involved in GO:0005896 interleukin-6 receptor complex
The interleukin-6 receptor complex is built from three core proteins and modulated by a network of signaling and regulatory genes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL6 | Ligand that binds IL6R and initiates complex assembly | CRISPR KO abolishes autocrine and paracrine signaling |
| IL6R | Alpha chain that binds IL-6 and recruits gp130 | Target of tocilizumab; KO distinguishes classic vs trans-signaling |
| IL6ST | gp130 signal-transducing subunit that dimerizes in the hexamer | Essential for JAK/STAT activation; KO is embryonic lethal in mice |
| JAK1 | Kinase that phosphorylates gp130 and STAT3 | Point mutations dissect kinase-dependent outputs |
| JAK2 | Kinase contributing to gp130 phosphorylation | Relevant to myeloproliferative and inflammatory models |
| TYK2 | Kinase associated with gp130 signaling | Modulates STAT3 activation in immune cells |
| STAT3 | Transcription factor activated downstream of gp130 | KO or knock-in of phospho-tyrosine reveals target genes |
| SOCS1 | Negative feedback inhibitor of JAK activity | Overexpression suppresses IL-6 signaling |
| SOCS3 | Feedback inhibitor induced by STAT3 | KO enhances and prolongs STAT3 activation |
| SHP2 | Phosphatase that attenuates gp130 signaling | Point mutation affects MAPK output |
| ADAM17 | Protease that sheds membrane IL6R to generate sIL-6R | KO reduces trans-signaling capacity |
| IL6ST soluble form | sgp130 decoy that inhibits trans-signaling | Overexpression blocks pro-inflammatory IL-6 actions |
| CNTF | Cytokine that can recruit gp130-containing receptor complexes | Engineered cytokines reveal shared gp130 usage |
| OSMR | Receptor subunit that can partner with gp130 | Relevant to CNTF and IL-6 family cross-talk |
| LIF | IL-6 family cytokine sharing gp130 | Comparative KO studies distinguish shared vs unique outputs |
| IL11 | IL-6 family cytokine with its own alpha receptor and gp130 | KO models clarify family redundancy |
| CRP | Acute-phase protein induced by IL-6 in liver | Readout of hepatic IL-6 receptor complex activity |
How Is interleukin-6 receptor complex Regulated?
Interleukin-6 receptor complex signaling is tightly regulated at multiple levels. SOCS1 and SOCS3 are induced by STAT3 and provide negative feedback that limits JAK activity and signal duration. Phosphatases such as SHP2 and receptor internalization further attenuate the response. The availability of membrane IL6R versus soluble sIL-6R determines whether classic or trans-signaling predominates, and ADAM17-mediated shedding controls sIL-6R generation. Soluble gp130 (sgp130) acts as a natural decoy that selectively neutralizes trans-signaling. These regulatory layers ensure that IL-6 outputs are context-dependent and reversible, and their dysfunction contributes to chronic inflammatory disease.
interleukin-6 receptor complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL6 | Cytokine storm, inflammation | IL6 knockout or overexpression in immune cells |
| IL6R | Rheumatoid arthritis, autoimmune disease | IL6R knockout and point-mutation knock-in |
| IL6ST | Cancer, inflammation, tissue regeneration | gp130 knock-in of signaling mutants |
| STAT3 | Cancer, autoimmunity | STAT3 knockout or phospho-mutant knock-in |
| ADAM17 | Trans-signaling in inflammation | ADAM17 knockout to block sIL-6R shedding |
Cytokine storm and hyperinflammation
Excessive interleukin-6 receptor complex signaling is a hallmark of cytokine storm syndromes, including CAR-T-cell-associated cytokine release syndrome and severe viral infections. IL-6 blockade with tocilizumab or other inhibitors is used clinically to dampen these life-threatening inflammatory responses. The hexameric complex is therefore a direct therapeutic node in hyperinflammatory states.
Chronic inflammation and autoimmune disease
Persistent activation of IL-6 signaling contributes to rheumatoid arthritis, inflammatory bowel disease, and other autoimmune conditions. Trans-signaling via sIL-6R is particularly associated with the pro-inflammatory arm of IL-6 biology, making it an attractive selective target. Selective inhibition of trans-signaling with sgp130Fc has been explored to preserve regenerative classic signaling.
Cancer
IL-6 receptor complex signaling promotes tumor cell proliferation, survival, and angiogenesis, and is frequently elevated in cancers such as multiple myeloma and hepatocellular carcinoma. STAT3 activation downstream of gp130 supports an immunosuppressive tumor microenvironment. Targeting IL-6, IL6R, or gp130 is therefore an active area of oncology drug development.
Liver pathophysiology
In the liver, IL-6 controls acute-phase protein synthesis, regeneration, and metabolic homeostasis. Dysregulated hepatic IL-6 signaling contributes to fatty liver disease, fibrosis, and hepatocellular carcinoma. The interleukin-6 receptor complex is thus central to both protective and pathogenic liver responses.
From interleukin-6 receptor complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL6 drive autocrine tumor growth? | IL6 knockout in cancer cell lines |
| What is the role of membrane IL6R versus sIL-6R? | IL6R knockout and sIL-6R overexpression |
| Which gp130 tyrosine motifs control STAT3 output? | gp130 point-mutation knock-in |
| How does IL-6 affect immune cell differentiation? | IL6 or IL6R knockout in primary immune cells |
| Can trans-signaling be selectively blocked? | sgp130Fc overexpression or knock-in |
| What genes are downstream of STAT3 in liver? | STAT3 knockout or tagged knock-in with RNA-seq |
How to Study the interleukin-6 receptor complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Testing dependence on IL6, IL6R, or IL6ST |
| Point-mutation knock-in | Specific residue function | Dissecting gp130 tyrosine motifs |
| RNA-seq | Transcriptional changes | Identifying IL-6 target genes |
| Phospho-STAT3 immunoblot | STAT3 activation | Measuring receptor complex signaling |
| ELISA | Cytokine and sIL-6R levels | Quantifying trans-signaling capacity |
| Co-immunoprecipitation | Protein-protein interactions | Detecting hexameric complex assembly |
| Luciferase reporter | STAT3 transcriptional activity | Screening inhibitors of IL-6 signaling |
| Flow cytometry | Surface IL6R and gp130 expression | Characterizing responsive cell populations |
CRISPR knockout and knock-in models
CRISPR-Cas9 knockout of IL6, IL6R, or IL6ST provides clean loss-of-function models to test which outputs depend on the hexameric complex. Knock-in of point mutations in gp130 cytoplasmic tyrosines allows dissection of individual signaling branches. These models are essential for distinguishing classic signaling from trans-signaling.
Transcriptomics and proteomics
RNA-seq after IL-6 stimulation or receptor knockout reveals the transcriptional programs controlled by the interleukin-6 receptor complex. Proteomics can quantify STAT3 phosphorylation and interactome changes. These approaches identify context-specific target genes in inflammation and cancer.
Imaging and biochemical assays
Fluorescence microscopy and co-immunoprecipitation can visualize assembly of the hexameric complex and gp130 dimerization. Surface plasmon resonance and ELISA measure ligand-receptor binding affinities and sIL-6R levels. These methods validate structural and stoichiometric predictions.
Functional signaling assays
STAT3 luciferase reporters, phospho-STAT3 immunoblotting, and cytokine secretion assays measure downstream activation of the interleukin-6 receptor complex. Acute-phase protein production such as CRP is a classic hepatic readout. These assays are used to test inhibitors and CRISPR perturbations.
How CRISPR Can Be Used to Study GO:0005896 interleukin-6 receptor complex
Knockout
CRISPR knockout of IL6, IL6R, or IL6ST abolishes interleukin-6 receptor complex formation and downstream signaling, providing a clean background to test which cellular responses require the hexameric complex. Knockout of ADAM17 prevents sIL-6R shedding and selectively impairs trans-signaling.
Point Mutation
Point-mutation knock-in of specific gp130 cytoplasmic tyrosines or JAK binding sites allows precise mapping of which residues couple the complex to STAT3, MAPK, or PI3K outputs. Such models are critical for understanding how a single receptor complex can produce diverse biological effects.
Knock-in
Knock-in of epitope tags or fluorescent reporters into IL6R or IL6ST enables live-cell imaging and proteomic analysis of the assembled complex. Knock-in of human IL6R or sIL-6R variants can model species-specific signaling and disease-associated alleles.
Overexpression
Overexpression of IL6, sIL-6R, or sgp130Fc in cell lines or animal models amplifies or blocks specific arms of the pathway, respectively. Overexpression models are widely used to study cytokine storm and cancer progression driven by the interleukin-6 receptor complex.
How EDITGENE Supports interleukin-6 receptor complex Research
Researchers studying interleukin-6 receptor complex-related genes often need to determine whether a candidate gene is causally involved in a specific inflammatory, metabolic, or oncogenic phenotype. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions with publication-grade rigor.
Contact EDITGENE today to design your custom CRISPR model for interleukin-6 receptor complex research.
Frequently Asked Questions About interleukin-6 receptor complex
What is the interleukin-6 receptor complex?
It is a hexameric protein assembly (GO:0005896) made of two IL-6 molecules, two IL-6 receptor alpha chains, and two gp130 subunits that transmits IL-6 signals into cells.
What genes are involved in the interleukin-6 receptor complex?
The core genes are IL6, IL6R, and IL6ST (gp130), with downstream signaling through JAK1, JAK2, TYK2, and STAT3.
What is the difference between classic and trans-signaling?
Classic signaling uses membrane-bound IL6R, while trans-signaling uses soluble IL-6R to activate gp130 on cells lacking membrane IL6R, and is linked to pro-inflammatory effects.
Which diseases involve the interleukin-6 receptor complex?
Cytokine storm syndromes, rheumatoid arthritis, inflammatory bowel disease, liver disease, and multiple cancers involve dysregulated IL-6 receptor complex signaling.
How is the interleukin-6 receptor complex targeted therapeutically?
Tocilizumab blocks IL-6R, while sgp130Fc selectively inhibits trans-signaling, and JAK inhibitors block downstream kinase activity.
What is the stoichiometry of the interleukin-6 receptor complex?
It is a hexamer with two molecules each of IL-6, IL6R, and gp130.
How do CRISPR knockouts help study IL-6 signaling?
Knockout of IL6, IL6R, or IL6ST abolishes complex formation and reveals which cellular responses depend on the hexameric receptor.
What cell models are used to study IL-6 trans-signaling?
Cells lacking membrane IL6R but expressing gp130, combined with sIL-6R overexpression or ADAM17 knockout, are standard models.
What readouts measure interleukin-6 receptor complex activity?
Phospho-STAT3 immunoblotting, STAT3 luciferase reporters, acute-phase protein production such as CRP, and RNA-seq are common readouts.
Why is gp130 important in the interleukin-6 receptor complex?
gp130 is the signal-transducing subunit; its dimerization activates JAKs and STAT3, making it essential for all IL-6 family cytokine signaling.
Conclusion
The interleukin-6 receptor complex (GO:0005896) is a hexameric cellular component that converts IL-6 binding into diverse transcriptional programs through gp130, JAK, and STAT3. Its dual capacity for classic and trans-signaling explains the pleiotropic and sometimes opposing roles of IL-6 in inflammation, immunity, metabolism, and cancer. Because dysregulated assembly or activation of this complex underlies cytokine storm, autoimmune disease, and tumor progression, it remains a high-value target for therapeutic intervention. CRISPR-based knockout, knock-in, and overexpression models are indispensable for dissecting the precise contributions of each subunit and signaling branch, and for validating candidate drugs that selectively modulate this pathway.
References
- 1. Rose-John S et al.. 2023. Targeting IL-6 trans-signalling: past, present and future prospects.. Nat Rev Immunol 23(10):666-681 PMID: 37069261
- 2. Scheller J et al.. 2011. The pro- and anti-inflammatory properties of the cytokine interleukin-6.. Biochim Biophys Acta 1813(5):878-88 PMID: 21296109
- 3. Barrett D. 2024. IL-6 Blockade in Cytokine Storm Syndromes.. Adv Exp Med Biol 1448:565-572 PMID: 39117839
- 4. Rose-John S. 2012. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.. Int J Biol Sci 8(9):1237-47 PMID: 23136552
- 5. Schmidt-Arras D et al.. 2016. IL-6 pathway in the liver: From physiopathology to therapy.. J Hepatol 64(6):1403-15 PMID: 26867490
- 6. Simpson RJ et al.. 1997. Interleukin-6: structure-function relationships.. Protein Sci 6(5):929-55 PMID: 9144766
- 7. Rafii P et al.. 2024. Engineered interleukin-6-derived cytokines recruit artificial receptor complexes and disclose CNTF signaling via the OSMR.. J Biol Chem 300(5):107251 PMID: 38569939
- 8. Garbers C et al.. 2018. Interleukin-6: designing specific therapeutics for a complex cytokine.. Nat Rev Drug Discov 17(6):395-412 PMID: 29725131
